Further research is needed to verify whether the hepatic expression of adropin correlates with adropin circulating levels, and to investigate the extent to which changes in adropin have the potential to prevent or limit the metabolic and endocrine defects associated with fatty liver/NAFLD. This evidence concerns the gene ENHO and fatty liver disease.